AbbVie, Inc. (ABBV)
259.83
+3.41
(+1.33%)
USD |
NYSE |
Sep 01, 16:00
259.95
+0.12
(+0.05%)
After-Hours: 20:00
AbbVie Cash from Investing (Quarterly) : -1.197B for June 30, 2026
Cash from Investing (Quarterly) Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Cash from Investing (Quarterly) Data
| Date | Value |
|---|---|
| June 30, 2026 | -1.197B |
| March 31, 2026 | -574.00M |
| December 31, 2025 | -1.463B |
| September 30, 2025 | -3.264B |
| June 30, 2025 | -1.181B |
| March 31, 2025 | -735.00M |
| December 31, 2024 | -1.874B |
| September 30, 2024 | -8.256B |
| June 30, 2024 | -1.102B |
| March 31, 2024 | -9.588B |
| December 31, 2023 | -800.00M |
| September 30, 2023 | -369.00M |
| June 30, 2023 | -341.00M |
| March 31, 2023 | -499.00M |
| December 31, 2022 | -448.00M |
| September 30, 2022 | 1.286B |
| June 30, 2022 | 130.00M |
| March 31, 2022 | -1.591B |
| December 31, 2021 | -1.145B |
| September 30, 2021 | -615.00M |
| June 30, 2021 | -242.00M |
| March 31, 2021 | -342.00M |
| December 31, 2020 | -627.00M |
| September 30, 2020 | -1.149B |
| June 30, 2020 | -35.65B |
| Date | Value |
|---|---|
| March 31, 2020 | -129.00M |
| December 31, 2019 | -615.00M |
| September 30, 2019 | 1.378B |
| June 30, 2019 | -140.00M |
| March 31, 2019 | -27.00M |
| December 31, 2018 | -283.00M |
| September 30, 2018 | -963.00M |
| June 30, 2018 | 687.00M |
| March 31, 2018 | -447.00M |
| December 31, 2017 | 201.00M |
| September 30, 2017 | -109.00M |
| June 30, 2017 | 318.00M |
| March 31, 2017 | -684.00M |
| December 31, 2016 | -119.00M |
| September 30, 2016 | -199.00M |
| June 30, 2016 | -4.298B |
| March 31, 2016 | -1.458B |
| December 31, 2015 | -297.00M |
| September 30, 2015 | 745.00M |
| June 30, 2015 | -12.51B |
| March 31, 2015 | -873.00M |
| December 31, 2014 | 2.514B |
| September 30, 2014 | -2.284B |
| June 30, 2014 | -359.00M |
| March 31, 2014 | -797.00M |
Cash From Investing Definition
Represents the net cash flow from the company's investing activities. Investing activities represent the movement in the company's long-term assets.
Cash from Investing (Quarterly) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Cash from Investing (Quarterly) Benchmarks
| Biogen, Inc. | -3.839B |
| Gilead Sciences, Inc. | -10.35B |
| Regeneron Pharmaceuticals, Inc. | -92.70M |
| Amgen, Inc. | -569.00M |
| REGENXBIO, Inc. | 65.92M |
Cash from Investing (Quarterly) Related Metrics
| Cash from Operations (Quarterly) | 3.436B |
| Cash from Financing (Quarterly) | -5.054B |
| Free Cash Flow | 18.21B |
| Free Cash Flow Per Share (Quarterly) | 1.758 |
| Free Cash Flow to Equity (Quarterly) | 5.15B |
| Free Cash Flow to Firm (Quarterly) | 3.780B |
| Free Cash Flow Yield | 3.95% |